Novel human-derived EML4-ALK fusion cell lines identify ribonucleotide reductase RRM2 as a target of activated ALK in NSCLC.
Bokhari AA, Lai WY, Le AT, Gabre JL, Chuang TP, Fransson S, Bergman B, Djos A, Chen N, Martinsson T, Van den Eynden J, Doebele RC, Palmer RH, Hallberg B, Umapathy G.
Bokhari AA, et al. Among authors: palmer rh.
Lung Cancer. 2022 Sep;171:103-114. doi: 10.1016/j.lungcan.2022.07.010. Epub 2022 Jul 25.
Lung Cancer. 2022.
PMID: 35933914
Free article.